GeneDx Holdings Corp. Class A Common Stock
GeneDx Holdings Corp. Class A Common Stock price
About GeneDx Holdings Corp. Class A Common Stock
GeneDx Holdings Corp., a genomics company, provides genetic testing services. The company primarily offers pediatric and rare disease diagnostics with a focus on whole exome and genome sequencing, as well as data and information services. It also develops an AI-based platform for next generation sequencing analysis, interpretation, and clinical reporting for rare disease, hereditary risk, and cancer testing. GeneDx Holdings Corp. was founded in 2000 and is headquartered in Stamford, Connecticut.
- Stock ticker
- WGS
- Company
- GeneDx Holdings Corp.
- Industry
- Healthcare
- Category
- US
- Stock split / reverse split
- 331
- Launch date
- Nov 4, 2020
- Listed exchange
- NASDAQ
Financials
Summary: WGS reported Revenue of 114.44M (+11.44%), beating expectations; EPS of 0.01 (-98.00%), beating expectations.
Dividends
GeneDx Holdings Corp. Class A Common Stock conversion tables
 |  |
|---|---|
| 0.5 WGS | 33.9 USD |
| 1 WGS | 67.8 USD |
| 5 WGS | 339.04 USD |
| 10 WGS | 678.09 USD |
| |
|---|---|
| 0.5 USD | 0.0073737 WGS |
| 1 USD | 0.014747 WGS |
| 5 USD | 0.073737 WGS |
| 10 USD | 0.14747 WGS |
More to explore
FAQ
WGS is trading at $67.81, -1.64% over the last 24 hours. Track live moves on the price chart at the top of this page.
The WGS stock forecast depends on a mix of factors — broader market conditions, sector trends, and company-specific drivers like earnings, product cycles, and macro signals. WGS is currently trading at $67.81, -1.64% over the last 24 hours, which reflects how the market is pricing these factors today. For a longer-term outlook on WGS price action, review the 30-day, 60-day, and 90-day performance shown above, monitor momentum across the Healthcare sector, and watch overall market sentiment. Stock forecasts and price predictions are inherently uncertain — always DYOR.
P/E ratio (Price-to-Earnings, trailing twelve months) measures how much investors pay per dollar of earnings over the last 12 months. WGS's P/E ratio is currently -- — calculated by dividing its share price by its trailing 12-month earnings per share (EPS). A higher P/E suggests investors expect stronger future growth from WGS; a lower P/E may indicate the stock is undervalued or that the market is pricing in a weaker outlook. P/E ratios are most useful when compared against WGS's historical range and other companies in the Healthcare sector.
GeneDx Holdings Corp.'s market cap is currently 2.09B USD. Market cap is calculated as stock price × total shares outstanding.
Disclaimer
The social content on this page ("Content"), including but not limited to tweets and statistics provided by LunarCrush, is sourced from third parties and provided "as is" for informational purposes only. OKX does not guarantee the quality or accuracy of the Content, and the Content does not represent the views of OKX. It is not intended to provide (i) investment advice or recommendation; (ii) an offer or solicitation to buy, sell or hold digital assets; or (iii) financial, accounting, legal or tax advice. Digital assets, including stablecoins and NFTs, involve a high degree of risk and can fluctuate greatly. The price and performance of the digital assets are not guaranteed and may change without notice.
OKX does not provide investment or asset recommendations. You should carefully consider whether trading or holding digital assets is suitable for you in light of your financial condition. Please consult your legal/tax/investment professional for questions about your specific circumstances. For further details, please refer to our Terms of Use and Risk Warning.